Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds. (ToxHD)
Primary Purpose
Hailey-Hailey Disease, Darier Disease
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Botulism Toxin Treatment
Sponsored by
About this trial
This is an interventional other trial for Hailey-Hailey Disease focused on measuring Botulism Toxin
Eligibility Criteria
Inclusion Criteria:
- Confirmed diagnosis (clinical and histological features) of Hailey Hailey or Darier diseases.
- Moderate to very severe lesions located in large folds
- Patient aged 18 ans or more
- Patient with health coverage
- Patient who have signed the consent form
- Patient proficient into filling out the questionnaires.
Exclusion Criteria:
- Hypersensibility to toxin or excipients
- Myastheny
- Deglutition's problems
- Past medical history of dysphagia or aspiration pneumonia
- Pregnancy (positive B-HCG test performed a maxima 72h before) or breastfeeding
- Mental , physical incapacity to fill in the questionnaires
- Guardianship patients
- Skin infections at the inclusion visit
- Application in the last 7 days at the site of injection of local treatments (apart emollients or antiseptics) or injections of botulism toxin or dynamic phototherapy or laser in the last 6 months.
- Systemic treatment with aminosides in the last 15 days
- Inclusion in another study in the last 2 months.
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Botulism Toxin treatment
Arm Description
Injection of 50 UI Botulism toxin for the treated zone
Outcomes
Primary Outcome Measures
Evaluation of quality of life measured by change in the DLQI score
Variation of DLQI score between Baseline and M1
Secondary Outcome Measures
Evaluation of quality of life measured by change in the DLQI score
Variation of DLQI score between Baseline and M3
Evaluation of quality of life measured by change in the DLQI score
Variation of DLQI score between Baseline and M6
Evaluation of skin improvement in treated areas using change the IGA score
Variation of IGA score between Baseline and M1
Evaluation of skin improvement in treated areas using change the IGA score
Variation of IGA score between Baseline and M3
Evaluation of skin improvement in treated areas using change the IGA score
Variation of IGA score between Baseline and M6
Evaluation of psychosocial impairment at measured by change in the HidroQoL score
Variation of HidroQoL score between Baseline and M1
Evaluation of psychosocial impairment measured by change in the HidroQoL score
Variation of HidroQoL score between Baseline and M3
Evaluation of psychosocial impairment measured by change in the HidroQoL score
Variation of HidroQoL score between Baseline and M6
Evaluation by the investigator of the treated lesions global severity change as assessed by comparison using measurement of the affected area
Variation of treated lesions severity between Baseline and M1
Evaluation by the investigator of the treated lesions global severity change as assessed by comparison using measurement of the affected area
Variation of treated lesions severity between Baseline and M3
Evaluation by the investigator of the treated lesions global severity change as assessed by comparison using measurement of the affected area
Variation of treated lesions severity between Baseline and M6
Evaluation of patient's satisfaction Using the IGA score " Improvement Global Assessment "
Evaluation of patient treatment acceptability using visual analogic pain scale
Evaluation of acceptability over the medium to long term as assessed by occurence of side effects
Evaluation of acceptability over the medium to long term as assessed by occurence of side effects
Evaluation of acceptability over the medium to long term as assessed by occurence of side effects
Evaluation of long term efficacy as assessed by percentage of non-responder patients with IGA score egal to 0
Evaluation of long term efficacy as assessed by delay for significant relapse (reappearance of skin lesions justifying treatment)
Evaluation of long term efficacy as assessed by comparison between the number of infection episodes occurred during the 6 months before the study or during the 6 months of the study
Full Information
NCT ID
NCT02782702
First Posted
May 20, 2016
Last Updated
November 29, 2021
Sponsor
University Hospital, Toulouse
1. Study Identification
Unique Protocol Identification Number
NCT02782702
Brief Title
Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds.
Acronym
ToxHD
Official Title
Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds. Toxin Hailey Darier
Study Type
Interventional
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
September 2015 (undefined)
Primary Completion Date
November 2017 (Actual)
Study Completion Date
November 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Toulouse
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Hailey Hailey and Darier disease are rare genetic dermatoses. Mutations of 2 genes (ATP2C1 or ATP2A2 respectively) are responsible for the diseases. These genes have a key role in calcium pump; their defect create abnormal link between keratinocytes' desmosomes and induce skin lesions. Clinically, patients present with inflammatory lesions located in the folds. Quality of life is impaired because of pain, pruritus and tendency to infections. Lesions are permanent but acute exacerbations occur in hot seasons because of increased sweating. Usual therapies are often not effective (local treatment, laser, phototherapy). Because sweating is a well established inducing or aggravating factor, botulism toxin could be an effective treatment for these diseases.
Botulism toxin is already used in clinical practice and acts via a decreased sweet secretion. Improvement of skin lesions in Hailey-Hailey or Darier diseases has been previously reported in a few cases but there is no study properly evaluating the benefit of such treatment.
The aim of the project is to study the improvement of quality of life for patients suffering from Hailey-Hailey or Darier diseases after a injections of botulism toxin in large skin folds. The principal objective is to estimate the distribution of the variation of quality of life at M1 vs. baseline.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hailey-Hailey Disease, Darier Disease
Keywords
Botulism Toxin
7. Study Design
Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Botulism Toxin treatment
Arm Type
Experimental
Arm Description
Injection of 50 UI Botulism toxin for the treated zone
Intervention Type
Drug
Intervention Name(s)
Botulism Toxin Treatment
Intervention Description
Injection of 50 UI of botulism toxin for treated zone
Primary Outcome Measure Information:
Title
Evaluation of quality of life measured by change in the DLQI score
Description
Variation of DLQI score between Baseline and M1
Time Frame
Day 0 and day 30
Secondary Outcome Measure Information:
Title
Evaluation of quality of life measured by change in the DLQI score
Description
Variation of DLQI score between Baseline and M3
Time Frame
Day 0 and day 90
Title
Evaluation of quality of life measured by change in the DLQI score
Description
Variation of DLQI score between Baseline and M6
Time Frame
Day 0 and day 180
Title
Evaluation of skin improvement in treated areas using change the IGA score
Description
Variation of IGA score between Baseline and M1
Time Frame
Day 0 and Day 30
Title
Evaluation of skin improvement in treated areas using change the IGA score
Description
Variation of IGA score between Baseline and M3
Time Frame
Day 0 and Day 90
Title
Evaluation of skin improvement in treated areas using change the IGA score
Description
Variation of IGA score between Baseline and M6
Time Frame
Day 0 and Day 180
Title
Evaluation of psychosocial impairment at measured by change in the HidroQoL score
Description
Variation of HidroQoL score between Baseline and M1
Time Frame
Day 0 and Day 30
Title
Evaluation of psychosocial impairment measured by change in the HidroQoL score
Description
Variation of HidroQoL score between Baseline and M3
Time Frame
Day 0 and Day 90
Title
Evaluation of psychosocial impairment measured by change in the HidroQoL score
Description
Variation of HidroQoL score between Baseline and M6
Time Frame
Day 0 and Day 180
Title
Evaluation by the investigator of the treated lesions global severity change as assessed by comparison using measurement of the affected area
Description
Variation of treated lesions severity between Baseline and M1
Time Frame
Day 0 and Day 30
Title
Evaluation by the investigator of the treated lesions global severity change as assessed by comparison using measurement of the affected area
Description
Variation of treated lesions severity between Baseline and M3
Time Frame
Day 0 and Day 90
Title
Evaluation by the investigator of the treated lesions global severity change as assessed by comparison using measurement of the affected area
Description
Variation of treated lesions severity between Baseline and M6
Time Frame
Day 0 and Day 180
Title
Evaluation of patient's satisfaction Using the IGA score " Improvement Global Assessment "
Time Frame
Day 180
Title
Evaluation of patient treatment acceptability using visual analogic pain scale
Time Frame
Day 0 after injection
Title
Evaluation of acceptability over the medium to long term as assessed by occurence of side effects
Time Frame
Day 30
Title
Evaluation of acceptability over the medium to long term as assessed by occurence of side effects
Time Frame
Day 90
Title
Evaluation of acceptability over the medium to long term as assessed by occurence of side effects
Time Frame
Day 180
Title
Evaluation of long term efficacy as assessed by percentage of non-responder patients with IGA score egal to 0
Time Frame
Day 30
Title
Evaluation of long term efficacy as assessed by delay for significant relapse (reappearance of skin lesions justifying treatment)
Time Frame
Up to 180 days
Title
Evaluation of long term efficacy as assessed by comparison between the number of infection episodes occurred during the 6 months before the study or during the 6 months of the study
Time Frame
Up to 180 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Confirmed diagnosis (clinical and histological features) of Hailey Hailey or Darier diseases.
Moderate to very severe lesions located in large folds
Patient aged 18 ans or more
Patient with health coverage
Patient who have signed the consent form
Patient proficient into filling out the questionnaires.
Exclusion Criteria:
Hypersensibility to toxin or excipients
Myastheny
Deglutition's problems
Past medical history of dysphagia or aspiration pneumonia
Pregnancy (positive B-HCG test performed a maxima 72h before) or breastfeeding
Mental , physical incapacity to fill in the questionnaires
Guardianship patients
Skin infections at the inclusion visit
Application in the last 7 days at the site of injection of local treatments (apart emollients or antiseptics) or injections of botulism toxin or dynamic phototherapy or laser in the last 6 months.
Systemic treatment with aminosides in the last 15 days
Inclusion in another study in the last 2 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Aude MAZA RIOLAND, MD
Organizational Affiliation
University Hospital, Toulouse
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
33602313
Citation
Dreyfus I, Maza A, Rodriguez L, Merlos M, Texier H, Rousseau V, Sommet A, Mazereeuw-Hautier J. Botulinum toxin injections as an effective treatment for patients with intertriginous Hailey-Hailey or Darier disease: an open-label 6-month pilot interventional study. Orphanet J Rare Dis. 2021 Feb 18;16(1):93. doi: 10.1186/s13023-021-01710-x.
Results Reference
result
Learn more about this trial
Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds.
We'll reach out to this number within 24 hrs